TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase IIIb Open-label run-in Double-blind, Placebo Controlled, Randomized Study to Evaluate the Safety/Efficacy of Certolizumab Pegol Administered Concomitantly With Stable-dose Methotrexate in Patients With Active Rheumatoid Arthritis.
Brief Summary: During the run-in period, CZP will be administered at 400 mg (2 injections) at Wks 0, 2, and 4 and 200 mg with placebo (1 injection placebo, 1 injection CZP) at Wks 6, 8, 10, 12, 14 and 16. At Wk 18 patients will be grouped as responders or non-responders based on results of the ACR20 at Week 16.


Options:
A: Arm Label: Arm 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept, Drug: methotrexate, Drug: Placebo, triple | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: methotrexate, Drug: Sulfasalazine, Drug: Hydroxychloroquine, Drug: Placebo, etanercept | Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: methotrexate; Assigned to Arm(s): Arm 1, Arm 2 | Intervention Type: DRUG; Name: Sulfasalazine; Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: Hydroxychloroquine; Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: Placebo, triple; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Placebo, etanercept; Assigned to Arm(s): Arm 2
B: Arm Label: Subcutaneous (SC) Abatacept; Type: ACTIVE_COMPARATOR; Interventions: Drug: Subcutaneous (SC) Abatacept | Arm Label: Intravenous (IV) Abatacept; Type: ACTIVE_COMPARATOR; Interventions: Drug: Intravenous (IV) Abatacept | Intervention Type: DRUG; Name: Subcutaneous (SC) Abatacept; Assigned to Arm(s): Subcutaneous (SC) Abatacept | Intervention Type: DRUG; Name: Intravenous (IV) Abatacept; Assigned to Arm(s): Intravenous (IV) Abatacept
C: Arm Label: Abatacept; Type: ACTIVE_COMPARATOR; Interventions: Drug: Abatacept | Arm Label: Adalimumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Adalimumab | Intervention Type: DRUG; Name: Abatacept; Assigned to Arm(s): Abatacept | Intervention Type: DRUG; Name: Adalimumab; Assigned to Arm(s): Adalimumab
D: Arm Label: Certolizumab pegol 400 mg and placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Certolizumab pegol, Other: Placebo | Arm Label: Certolizumab pegol 200 mg and placebo; Type: EXPERIMENTAL; Interventions: Drug: Certolizumab pegol, Other: Placebo | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Certolizumab pegol; Assigned to Arm(s): Certolizumab pegol 400 mg and placebo | Intervention Type: DRUG; Name: Certolizumab pegol; Assigned to Arm(s): Certolizumab pegol 200 mg and placebo | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Certolizumab pegol 200 mg and placebo, Certolizumab pegol 400 mg and placebo, Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase IIIb Open-label run-in Double-blind, Placebo Controlled, Randomized Study to Evaluate the Safety/Efficacy of Certolizumab Pegol Administered Concomitantly With Stable-dose Methotrexate in Patients With Active Rheumatoid Arthritis.
Brief Summary: During the run-in period, CZP will be administered at 400 mg (2 injections) at Wks 0, 2, and 4 and 200 mg with placebo (1 injection placebo, 1 injection CZP) at Wks 6, 8, 10, 12, 14 and 16. At Wk 18 patients will be grouped as responders or non-responders based on results of the ACR20 at Week 16.


Options:
A: Arm Label: Certolizumab pegol 400 mg and placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Certolizumab pegol, Other: Placebo | Arm Label: Certolizumab pegol 200 mg and placebo; Type: EXPERIMENTAL; Interventions: Drug: Certolizumab pegol, Other: Placebo | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Certolizumab pegol; Assigned to Arm(s): Certolizumab pegol 400 mg and placebo | Intervention Type: DRUG; Name: Certolizumab pegol; Assigned to Arm(s): Certolizumab pegol 200 mg and placebo | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Certolizumab pegol 200 mg and placebo, Certolizumab pegol 400 mg and placebo, Placebo
B: Arm Label: Golimumab (CNTO 148) with Methotrexate (MTX); Type: EXPERIMENTAL; Interventions: Drug: Golimumab, Drug: MTX | Arm Label: Infliximab with MTX; Type: EXPERIMENTAL; Interventions: Drug: MTX, Drug: Infliximab | Arm Label: Placebo with MTX; Type: PLACEBO_COMPARATOR; Interventions: Drug: MTX, Drug: Placebo | Intervention Type: DRUG; Name: Golimumab; Assigned to Arm(s): Golimumab (CNTO 148) with Methotrexate (MTX) | Intervention Type: DRUG; Name: MTX; Assigned to Arm(s): Golimumab (CNTO 148) with Methotrexate (MTX), Infliximab with MTX, Placebo with MTX | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo with MTX | Intervention Type: DRUG; Name: Infliximab; Assigned to Arm(s): Infliximab with MTX
C: N/A
D: Arm Label: Open-Label Active Treatment Enrolled from Phase 2; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Open-Label Active Treatment Enrolled from Phase 3; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Open-Label Active Treatment Enrolled from Phase 2 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Open-Label Active Treatment Enrolled from Phase 3

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: This study will examine whether the implementation of an outreach program that employs a tracking/reminder/recall/home visiting strategy will have any impact on receipt of immunizations and preventive care among urban adolescents.


Options:
A: Arm Label: Outreach; Type: OTHER; Interventions: Other: outreach services | Arm Label: Standard of Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: outreach services; Assigned to Arm(s): Outreach
B: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: AFIX In-Person Visit; Type: EXPERIMENTAL; Interventions: Other: Assessment , Feedback, Incentives, and eXchange Program | Arm Label: AFIX Webinar Visit; Type: EXPERIMENTAL; Interventions: Other: Assessment , Feedback, Incentives, and eXchange Program | Intervention Type: OTHER; Name: Assessment , Feedback, Incentives, and eXchange Program; Assigned to Arm(s): AFIX In-Person Visit, AFIX Webinar Visit
C: Arm Label: Intervention Practices; Type: EXPERIMENTAL; Interventions: Behavioral: Multimodal Vaccine Program | Arm Label: Control Practices; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Multimodal Vaccine Program; Assigned to Arm(s): Intervention Practices
D: Arm Label: Education about HPV by school nurse; Type: EXPERIMENTAL; Interventions: Behavioral: Education about HPV by school nurse | Arm Label: Control group 1; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Education about HPV by school nurse; Assigned to Arm(s): Education about HPV by school nurse

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: This study will examine whether the implementation of an outreach program that employs a tracking/reminder/recall/home visiting strategy will have any impact on receipt of immunizations and preventive care among urban adolescents.


Options:
A: Arm Label: Outreach; Type: OTHER; Interventions: Other: outreach services | Arm Label: Standard of Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: outreach services; Assigned to Arm(s): Outreach
B: Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Parent Only Group; Type: EXPERIMENTAL; Interventions: Other: Parent Only Phone Call | Arm Label: Parent and Adolescent Group; Type: EXPERIMENTAL; Interventions: Other: Parent and Adolescent Phone Call | Intervention Type: OTHER; Name: Parent Only Phone Call; Assigned to Arm(s): Parent Only Group | Intervention Type: OTHER; Name: Parent and Adolescent Phone Call; Assigned to Arm(s): Parent and Adolescent Group
C: Arm Label: Historical Cohort; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Reminder Recall Outreach; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Reminder-Recall-Outreach | Arm Label: Case Management; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Case Management | Arm Label: Patient Navigation; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Patient Navigator | Intervention Type: BEHAVIORAL; Name: Reminder-Recall-Outreach; Assigned to Arm(s): Reminder Recall Outreach | Intervention Type: BEHAVIORAL; Name: Case Management; Assigned to Arm(s): Case Management | Intervention Type: BEHAVIORAL; Name: Patient Navigator; Assigned to Arm(s): Patient Navigation
D: Arm Label: mailed reminder notice; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Mailed influenza vaccination reminder notice | Arm Label: No reminder notice; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Mailed influenza vaccination reminder notice; Assigned to Arm(s): mailed reminder notice

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Double Blind, Randomized Trial of Bosentan for Sarcoidosis Associated Pulmonary Hypertension
Brief Summary: Patients with advanced sarcoidosis often develop pulmonary hypertension. Pulmonary hypertension is a condition where the right side of the heart has to push the blood though the lungs at a higher pressure than normal. Since this pressure is higher, it is harder for the heart to pump the blood through the lungs to the left side of the body. If the blood can not get through the lungs, it can not get pumped through the rest of the body. This leads to weakness and shortness of breath. This type of hypertension does not usually respond to regular blood pressure medicines. The purpose of this study is to determine if bosentan (Tracleer) will help sarcoidosis associated pulmonary hypertension.


Options:
A: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: bosentan | Intervention Type: DRUG; Name: bosentan; Assigned to Arm(s): 2
B: Arm Label: Bosentan for 16 weeks; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bosentan | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Bosentan; Assigned to Arm(s): Bosentan for 16 weeks | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Bosentan; Assigned to Arm(s): Bosentan for 16 weeks | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Bosentan | Intervention Type: DRUG; Name: Bosentan; Assigned to Arm(s): 2
D: Arm Label: Combination ambrisentan + tadalafil; Type: ACTIVE_COMPARATOR; Interventions: Drug: ambrisentan, Drug: tadalafil | Arm Label: Monotherapy ambrisentan; Type: ACTIVE_COMPARATOR; Interventions: Drug: ambrisentan | Arm Label: Monotherapy tadalafil; Type: ACTIVE_COMPARATOR; Interventions: Drug: tadalafil | Intervention Type: DRUG; Name: ambrisentan; Assigned to Arm(s): Combination ambrisentan + tadalafil, Monotherapy ambrisentan | Intervention Type: DRUG; Name: tadalafil; Assigned to Arm(s): Combination ambrisentan + tadalafil, Monotherapy tadalafil

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Improving Otitis Media Care With EHR-based Clinical Decision Support and Feedback
Brief Summary: This protocol will prospectively develop a new electronic health record (EHR)-based health information technology (IT) intervention that a) summarizes Otitis Media (OM) care into clinically meaningful episodes-of-care, b) provides clinical decision support based upon evidence-based guidelines to primary care and ENT physicians working within an integrated physician network that uses a common EHR, and c) tests the additive effects on quality and resource utilization of providing feedback to physicians.


Options:
A: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: HIT Intervention without feedback; Type: EXPERIMENTAL; Interventions: Other: 3-Part Intervention | Arm Label: HIT Intervention with feedback; Type: EXPERIMENTAL; Interventions: Other: 4-Part Intervention | Arm Label: Feedback only; Type: EXPERIMENTAL; Interventions: Other: 1-part intervention | Intervention Type: OTHER; Name: 3-Part Intervention; Assigned to Arm(s): HIT Intervention without feedback | Intervention Type: OTHER; Name: 4-Part Intervention; Assigned to Arm(s): HIT Intervention with feedback | Intervention Type: OTHER; Name: 1-part intervention; Assigned to Arm(s): Feedback only
B: Arm Label: CDSS-D; Type: EXPERIMENTAL; Interventions: Other: Computerized Decision Support System for Depression (CDSS-D) | Arm Label: UC; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care (UC) | Intervention Type: OTHER; Name: Computerized Decision Support System for Depression (CDSS-D); Assigned to Arm(s): CDSS-D | Intervention Type: OTHER; Name: Usual Care (UC); Assigned to Arm(s): UC
C: Intervention Type: PROCEDURE; Name: Computer-Assisted diagnostic Decision Support; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: written diagnostic guidelines; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: electronic therapeutic reminders; Assigned to Arm(s): N/A
D: Intervention Type: OTHER; Name: educational intervention; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: internet-based intervention; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: evaluation of cancer risk factors; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: fecal occult blood test; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: screening colonoscopy; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Hypertension in Hemodialysis Patients
Brief Summary: We will directly test the hypothesis that an initial strategy of lisinopril-based therapy will be more effective than atenolol-based therapy in causing regression of left ventricular hypertrophy (LVH) over one year in patients with hemodialysis hypertension despite similar degree of BP reduction.


Options:
A: Intervention Type: DRUG; Name: epoetin alfa; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Hemodialysis | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Hemodialysis | Intervention Type: PROCEDURE; Name: Hemodialysis; Assigned to Arm(s): 1, 2
C: Arm Label: HD treated with standard dialysate; Type: ACTIVE_COMPARATOR; Interventions: Device: Standard dialysate (StDi) | Arm Label: post-dilution oHDF with standard dialysate; Type: ACTIVE_COMPARATOR; Interventions: Device: Standard dialysate (StDi) | Arm Label: pre-dilution oHDF with citrate dialysate; Type: EXPERIMENTAL; Interventions: Device: Citrate dialysate (CiDi) | Arm Label: HD treated with citrate dialysate; Type: EXPERIMENTAL; Interventions: Device: Citrate dialysate (CiDi) | Arm Label: post-dilution oHDF with citrate dialysate; Type: EXPERIMENTAL; Interventions: Device: Citrate dialysate (CiDi) | Arm Label: pre-dilution oHDF with standard dialysate; Type: ACTIVE_COMPARATOR; Interventions: Device: Standard dialysate (StDi) | Intervention Type: DEVICE; Name: Citrate dialysate (CiDi); Assigned to Arm(s): HD treated with citrate dialysate, post-dilution oHDF with citrate dialysate, pre-dilution oHDF with citrate dialysate | Intervention Type: DEVICE; Name: Standard dialysate (StDi); Assigned to Arm(s): HD treated with standard dialysate, post-dilution oHDF with standard dialysate, pre-dilution oHDF with standard dialysate
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atenolol | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Lisinopril | Intervention Type: DRUG; Name: Lisinopril; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Atenolol; Assigned to Arm(s): 1

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-Center, Open-Label, Continuation Trial LymphoStat-B™ Antibody (Monoclonal Anti-BLyS Antibody) in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase 2 Protocol LBSL02
Brief Summary: This is a continuation study to evaluate the long-term safety and efficacy of LymphoStat-B™ in subjects with SLE disease, that completed study LBSL02 and benefitted from treatment.


Options:
A: Arm Label: Belimumab 10 mg/kg; Type: EXPERIMENTAL; Interventions: Biological: Belimumab | Intervention Type: BIOLOGICAL; Name: Belimumab; Assigned to Arm(s): Belimumab 10 mg/kg
B: Arm Label: Belimumab 1 mg/kg; Type: EXPERIMENTAL; Interventions: Biological: Belimumab 1 mg/kg | Arm Label: Belimumab 10 mg/kg; Type: EXPERIMENTAL; Interventions: Biological: Belimumab 10 mg/kg | Intervention Type: BIOLOGICAL; Name: Belimumab 1 mg/kg; Assigned to Arm(s): Belimumab 1 mg/kg | Intervention Type: BIOLOGICAL; Name: Belimumab 10 mg/kg; Assigned to Arm(s): Belimumab 10 mg/kg
C: Arm Label: Placebo plus SOC; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Belimumab 1 mg/kg plus SOC; Type: EXPERIMENTAL; Interventions: Drug: Belimumab 1 mg/kg | Arm Label: Belimumab 4 mg/kg plus SOC; Type: EXPERIMENTAL; Interventions: Drug: Belimumab 4 mg/kg | Arm Label: Belimumab 10 mg/kg plus SOC; Type: EXPERIMENTAL; Interventions: Drug: Belimumab 10 mg/kg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo plus SOC | Intervention Type: DRUG; Name: Belimumab 1 mg/kg; Assigned to Arm(s): Belimumab 1 mg/kg plus SOC | Intervention Type: DRUG; Name: Belimumab 4 mg/kg; Assigned to Arm(s): Belimumab 4 mg/kg plus SOC | Intervention Type: DRUG; Name: Belimumab 10 mg/kg; Assigned to Arm(s): Belimumab 10 mg/kg plus SOC
D: Arm Label: Placebo plus standard therapy; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo, Drug: Standard therapy | Arm Label: Belimumab 200 mg SC plus standard therapy; Type: EXPERIMENTAL; Interventions: Biological: Belimumab 200 mg SC, Drug: Standard therapy | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo plus standard therapy | Intervention Type: BIOLOGICAL; Name: Belimumab 200 mg SC; Assigned to Arm(s): Belimumab 200 mg SC plus standard therapy | Intervention Type: DRUG; Name: Standard therapy; Assigned to Arm(s): Belimumab 200 mg SC plus standard therapy, Placebo plus standard therapy

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: 12-step Facilitation for the Dually Diagnosed
Brief Summary: This is a randomized trial testing the efficacy of a modified 12-step facilitation therapy for individuals with serious mental illness and alcohol use disorders, compared to usual treatment. 135 participants are randomized in 2:1 ratio to the modified 12-step facilitation (12 sessions of individual counseling) vs. treatment as usual. The primary hypothesis is that those receiving 12-step facilitation will have better drinking outcomes (percent days abstinence and drinks per drinking day)at end of treatment.


Options:
A: Arm Label: DDMI-IGT; Type: EXPERIMENTAL; Interventions: Behavioral: Dual-diagnosis motivational interviewing (DDMI), Behavioral: Integrated group therapy (IGT) | Arm Label: Usual care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Jail and community-based behavioral health services | Intervention Type: BEHAVIORAL; Name: Dual-diagnosis motivational interviewing (DDMI); Assigned to Arm(s): DDMI-IGT | Intervention Type: BEHAVIORAL; Name: Integrated group therapy (IGT); Assigned to Arm(s): DDMI-IGT | Intervention Type: BEHAVIORAL; Name: Jail and community-based behavioral health services; Assigned to Arm(s): Usual care
B: Arm Label: motivational interviewing; Type: EXPERIMENTAL; Interventions: Behavioral: Motivational Interviewing, Other: Treatment as usual | Arm Label: control group; Type: OTHER; Interventions: Other: Treatment as usual | Intervention Type: BEHAVIORAL; Name: Motivational Interviewing; Assigned to Arm(s): motivational interviewing | Intervention Type: OTHER; Name: Treatment as usual; Assigned to Arm(s): control group, motivational interviewing
C: Arm Label: IMR program; Type: EXPERIMENTAL; Interventions: Behavioral: Illness Management and Recovery (IMR) | Arm Label: Treatment as usual; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Illness Management and Recovery (IMR); Assigned to Arm(s): IMR program
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: 12-step facilitation | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Treatment as usual | Intervention Type: BEHAVIORAL; Name: 12-step facilitation; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Treatment as usual; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phosphorus Improvement Pilot Study
Brief Summary: Specific Aim: To determine the effect of a phosphorus additives educational intervention on serum phosphorus levels.

Hypothesis: Educating dialysis patients regarding phosphate containing additives will result in improved serum phosphorus levels.


Options:
A: Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Placebo | Arm Label: Intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Educational Intervention, Behavioral: Placebo | Intervention Type: BEHAVIORAL; Name: Educational Intervention; Assigned to Arm(s): Intervention | Intervention Type: BEHAVIORAL; Name: Placebo; Assigned to Arm(s): Control, Intervention
B: Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Usual care | Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Transplant navigator | Intervention Type: BEHAVIORAL; Name: Transplant navigator; Assigned to Arm(s): Intervention | Intervention Type: BEHAVIORAL; Name: Usual care; Assigned to Arm(s): Control
C: Arm Label: TALK Plus; Type: EXPERIMENTAL; Interventions: Behavioral: TALK PLUS | Arm Label: TALK Standard; Type: EXPERIMENTAL; Interventions: Behavioral: TALK Standard | Arm Label: Usual Care; Type: OTHER; Interventions: Behavioral: Usual Care | Intervention Type: BEHAVIORAL; Name: TALK PLUS; Assigned to Arm(s): TALK Plus | Intervention Type: BEHAVIORAL; Name: TALK Standard; Assigned to Arm(s): TALK Standard | Intervention Type: BEHAVIORAL; Name: Usual Care; Assigned to Arm(s): Usual Care
D: Arm Label: A; Type: EXPERIMENTAL; Interventions: Behavioral: dietary education | Intervention Type: BEHAVIORAL; Name: dietary education; Assigned to Arm(s): A

Answer: D